SLC2A5 and colonic neoplasm: Chałaśkiewicz et al. reported that the histone deacetylase inhibitor Trichostatin A upregulates SNAI1 and SNAI2 expression, resulting in suppression of SLC2A5 (GLUT5) expression in colon cancer cells and consequently enhancing their sensitivity to chemotherapeutic agents cisplatin and oxaliplatin 142.